Navigation Links
New Study Shows That Pharmacogenomics Could Benefit Patients, Spur Investment in Innovation
Date:8/3/2009

WASHINGTON, Aug. 3 /PRNewswire-USNewswire/ -- A new study funded by the National Pharmaceutical Council (NPC) shows that pharmacogenomics -- the field of scientific research focused on learning how genetic profiles predict the body's response to medicines - has the potential to lead to higher levels of research and development (R&D) investment and an increased pace of pharmaceutical innovation, offering substantial benefits for patients.

The study, "The Future Costs, Risks and Rewards of Drug Development: The Economics of Pharmacogenomics," was written by Joseph Cook and Graeme Hunter of NERA Economic Consulting and John Vernon of the University of North Carolina at Chapel Hill, and published in the July issue of PharmacoEconomics. According to the study, pharmacogenomics can provide more focused and targeted information to researchers during the R&D process, potentially reducing the number of patients needed for clinical trials as well as the cost and time required to complete the trials. Products could reach the market faster, providing a longer period of time over which the innovator companies could recoup the investment costs of developing products.

"We may see pharmacogenomics pushing us in the right direction of more investment in pharmaceuticals," said study author John Vernon. "The main features likely to drive this phenomenon are the ability of pharmacogenomics to drive adoption of drugs and lower costs of development and time to commercialization. Of course, we have yet to see how these factors are likely to play out, but pharmacogenomics has the makings of a powerful force for economic change and encouraging the financing of new drugs and treatments for patients."

For example, better information about the patients who are more likely to respond to a medication could increase the rate of use of that medicine. Biological markers also could help to identify patients for whom a drug may pose a significant risk of harm. Knowing which patients are not appropriate candidates for a certain drug may help increase the likelihood that a product that might otherwise have been dropped from development could make it to market and become available to treat those patients who could benefit. Thus, as companies make decisions about products to develop, the potential for a product to generate a positive return on investment could well be affected by the improved information that pharmacogenomics can offer. As the study notes, this could have important implications for patients in the U.S. through the improved availability of new pharmaceutical and biological innovations.

The authors caution, however, that because this is such a new field of study, "there is considerable uncertainty as to how the area will evolve, both clinically and economically." Although "the time horizon necessary for the science to develop and be adopted into clinical practice is not clear," the study does "shed some light on possible outcomes and provides researchers with a better understanding of the economics of pharmacogenomics."

"The ability to target medicines more specifically to patient groups is a significant change in the pharmaceutical landscape," said Dan Leonard, NPC President. "This study shows how pharmacogenomics can positively affect innovation and lead to increased benefits for patients."

NPC will continue to explore the issue of targeted, or personalized medicine, during an October 28 conference hosted in conjunction with the Personalized Medicine Coalition. Further information is available on NPC's website, www.npcnow.org.

To download a copy of the pharmacogenomics study, go to https://articleworks.cadmus.com/doc/dSoftcopy?o=807150&i=998589&c=1472827&atDownload=true

About the National Pharmaceutical Council

NPC's overarching mission is to sponsor and conduct scientific analyses of the appropriate use of biopharmaceuticals and the clinical and economic value of innovation. The organization's strategic focus is on evidence-based medicine (EBM) for health care decision-making, to ensure that patients have access to high-quality care. NPC was established in 1953 and is supported by the nation's major research-based biopharmaceutical companies. For more information, visit www.npcnow.org.


'/>"/>
SOURCE National Pharmaceutical Council
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 26, 2017 , ... MYOLYN, a medical technology company dedicated ... received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for two ... devices are stationary cycling systems that use MYOLYN’s patent-pending functional electrical stimulation ...
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab ... to be the preferred physical therapy provider for Derby City CrossFit, effective immediately. ... City CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will ...
(Date:4/25/2017)... IN (PRWEB) , ... April 25, 2017 , ... ... D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration could ... Financial will provide insight into what changes are most likely to make it ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Lake Park ... smiles by using Invisalign® in Lutz, FL. With the help of this ... and aesthetics with fewer potential complications, more discretion and less pain. , Drs. ...
(Date:4/25/2017)... RESTON, VIRGINIA (PRWEB) , ... April 25, 2017 ... ... scientists leading the way in unveiling cutting-edge birth defects research related to Zika ... recognized by the world’s premier society for this important science. , ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 Cardiology devices segment is anticipated to reach ... The Cardiology Devices segment is likely to create absolute $ ... 2018 over 2017. By the end of 2027, Cardiology Devices ... US$ 700 Mn, expanding at a CAGR of 18.4% over ... Asia Pacific reprocessed medical devices market in ...
(Date:4/19/2017)... , April 19, 2017 Global Surgical ... devices are tubes used to remove excess liquid and ... serum, pus, urine, bile or lymph. Surgical drains are ... surgery such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic ... prophylactic post-surgery to prevent accumulation of fluid e.g. blood ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
Breaking Medicine Technology: